India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

RoosterBio taps MineBio to supercharge hMSC & exosome solutions in China

Stereotaxis bags FDA clearance for next-gen cath lab tech

Asia emerges new hotspot for healthcare ransomware, says report

Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs

Trialt and Viedoc team up to transform clinical trials

The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners

WHO updates global guidelines to combat opioid crisis

Opioid dependence remains a major driver of death and disease worldwide

KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

Stipple Bio raises $100M Series A to advance next-gen cancer therapies

The new capital is expected to fund the company through 2029

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market